Enhanced Liver Fibrosis (ELF) Scores in Relation but Distinct Neonatal Populations

Abstract

Background. Infants in the neonatal ICU are at risk for developing parenteral nutrition associated liver disease (PNALD). Identifying patients progressing towards liver fibrosis earlier would allow for targeted liver protective therapies. Current markers to evaluate liver fibrosis are nonspecific or have significant risks. Enhanced liver fibrosis (ELF) scores have recently been used to identify and quantify liver fibrosis children and adults. Normative data has not been established in the neonatal population. Objective. Establish baseline ELF scores using hyaluronic acid (HA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and amino-terminal propeptide of type III collagen (PIIINP) in term (T), preterm (PT) and high risk infants (HR) for liver fibrosis.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 18, 2019
Accession Number
AD1081997

Entities

People

  • Cynthia Blanco
  • Diana Anzueto
  • Laura Keller
  • Stephanie Eighmy

Organizations

  • 59th Medical Wing

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Air Force
  • Body Weight
  • Cirrhosis
  • Department Of Defense
  • Disease Attributes
  • Diseases And Disorders
  • Education
  • Feeding Methods
  • Fibrosis
  • Health Services
  • Hepatic Stellate Cells
  • Hernia
  • Liver Diseases
  • Therapy

Fields of Study

  • Medicine

Readers

  • Immunology and Pathology
  • Oncology
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.